{
    "Trade/Device Name(s)": [
        "Wondfo Cocaine Urine Test",
        "Wondfo Methamphetamine Urine Test",
        "Cocaine Urine Test",
        "Methamphetamine Urine Test"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K112071",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020771"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO",
        "LAF"
    ],
    "Summary Letter Date": "September 7, 2011",
    "Summary Letter Received Date": "September 9, 2011",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3250",
        "21CFR862.3610"
    ],
    "Regulation Name(s)": [
        "Methamphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzoylecgonine",
        "D(+)-Methamphetamine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Cup",
        "Dip card"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow",
        "Competitive binding"
    ],
    "Methodologies": [
        "Antigen-antibody immunochemistry"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo Cocaine and Methamphetamine Urine Tests for qualitative detection of Benzoylecgonine and Methamphetamine in human urine",
    "Indications for Use Summary": "Qualitative determination of Benzoylecgonine (300 ng/mL cutoff) and D(+)-Methamphetamine (1000 ng/mL cutoff) in human urine for prescription and over-the-counter use; preliminary screening, requires confirmatory testing by GC/MS",
    "fda_folder": "Toxicology"
}